Were Medicaments Without Side Effects Are Produced

As regards low dose medicinal products, the production starts from the mother tincture, a special macerate that can be obtained from plants, buds, biochemical compounds or biological substances, according to the ancient preparation procedures of the traditional Homeopathic Pharmacopoeia.

The mother tincture is gradually and constantly diluted under a laminar flow hood in class 100, usually using a water-alcohol solution as a solvent.

At each dilution a dynamization procedure is performed, i.e., one vertical shaking that transmits physical-chemical specifications to the solution. The activation process is standardized through the use of the SKA (Sequential Kinetic Activation) method, designed and developed by our researchers.

This technique ensures a full bioavailability of the active ingredients and improves their therapeutic properties.

Sequential Kinetic Activation

Our production unit is authorized in accordance with international GMP standards. The production, control and storage of products take place in controlled particle contamination rooms, according to the strictest international standards.

We produce pellets, globules, and drops for oral use.

The production line is fully automated and produces both mono- and multi-component remedies.

All the qualitative, quantitative and microbiological controls required by the regulations on medicaments are carried out at our perfectly equipped production site. Guna, in an ideal synthesis between tradition and modernity, uses the most advanced scientific and technological breakthroughs in the production of its medicines, to give doctors and patients more and more effective medicaments without side effects, in compliance with the human being’s uniqueness.

In order to improve more and more the efficacy of our medicaments we are continuously developing basic and clinical researches. In the follow you may read some references of the publication supported by GUNA.

 

Published Papers

Year

Authors

Journal

Research type

Title

Molecules or compounds

2009

Gariboldi S. et al.

Pulmonary Pharmacology & Therapeutics

In vivo basic research

Low Dose oral administration of cytokines for treatment of allergic asthma.

IL-12

IFN-γ

2012

D’amico L. et al.

Journal of Cancer Therapy

Ex vivo basic research

Low Dose of IL-12 stimulates T Cell response in cultures of PBMCs derived from Non Small Cell Lung Cancer Patients.

IL-12

2013

Cardani D. et al.

Gastroenterology Research

In vivo basic research

Oral administration of Interleukin-10 and Anti-IL-1 Antibody ameliorates experimental intestinal inflammation.

IL-10

ANTI IL-1

2014

Roberti M. L. et al.

Journal of Biological Regulatory & Homeostatic Agents

Clinial Trial

Immunomodulating treatment with Low Dose interleukin-4, interleukin-10 and interleukin-11 in psoriasis vulgaris

IL-4

IL-10

2014

Radice E. et al.

International Immunopharmacology

Ex vivo basic research

Low Doses of sequential-kinetic-activated interferon-gamma enhance the ex vivo cytotoxicity of peripheral blood natural killer cells from patients with early-stage colorectal cancer. A preliminary study.

IFN-γ

2015

Luchetti P.

Minerva Medica Oftalmologica

Observational retrospective study

Increasing of visual function in patients with retinal atrophy treated with drugs of Low Dose Medicine.

NT3

NT4

NGF

2015

Barygina V. et al

Journal of Dermatological Science

In vitro basic research

Treatment with Low Dose cytokines reduces oxidative-mediated injury in perilesional keratinocytes from vitiligo skin.

IL-4

IL-10

FGF-β

β-endorphin

2015

Lotti T. et al

Journal of Biological Regulatory & Homeostatic Agents

Clinical Trial

Vitiligo: successful combination treatment based on oral Low Dose cytokines and di­fferent topical treatments.

IL-4

IL-10

ANTI IL-1

FGF-β

2015

Radice E. et al

Translational oncology

Ex vivo basic research

Enhancement of the immunomodulatory functions of ex vivo-generated dendritic cells from early-stage colon cancer patients by consecutive exposure to Low Doses of sequential kinetic activated IL-4 and IL-12. A preliminary study.

IL-4

IL-12

2015

Lotti T. et al

Der Hautarzt

Observational retrospective study

Successful combination treatment for Psoriasis with phototherapy and Low Dose Cytokines.

IL-4

IL-10

ANTI IL-1

2015

Tessaro et al.

Journal of Ovarian Research

In vivo basic research

Effect of oral administration of Low Dose follicle stimulating hormone on hyperandrogenized mice as amodel of polycystic ovary syndrome

FSH

2016

Barygina V. et al.

Journal of Dermatological Science

In vivo basic research

Low Dose cytokines reduce oxidative stress in primary lesional fibroblasts obtained from psoriatic patients.

IL-4

IL-10

FGF-β

β-ENDORPHIN

2016

Fiorito F. et al.

Comparative Immunology, Microbiology and Infectious Diseases

Veterinary study

Clinical improvement in feline herpesvirus 1 infected cats by oral Low Dose of interleukin-12 plus interferon-gamma.

IL-12

IFN-γ

2016

Genazzani A. et al Frontiers in Gynecological Endocrinology Observational study Pharmacological and Integrative Treatment of Stress-Induced Hypothalamic Amenorrhea.

β-ESTRADIOL

 

2016

Uberti F. et al

Cells Tissues Organs

In vitro basic research

Stimulation of the Non-neuronal Cholinergic System by Highly Diluted Acetylcholine in Keratinocytes.

 

ACH

2017

Tessaro I. et al.

J Reprod Infertil.

In vivo basic research

Ultra Low Dose of Follicle Stimulating Hormone and Progesterone attenuate the Severity of Polycystic Ovary Syndrome Features in a Hyperandrogenized Mouse Model.

FSH

PROGESTERON

2017

Martin Martin L. S. et al. Drud Design, Development and Therapy Clinical Trial An open randomized active-controlled clinical trial with Low Dose SKA cytokines versus DMARDs evaluating low disease activity maintenance in patients with rheumatoid arthritis.

ANTI IL-1

IL-4

IL-10

2017

Carello R. et al.

Italian Journal of Pediatrics

Clinical Trial

Long-term treatment with Low Dose Medicine in chronic childhood eczema. A double-blind two-stage randomized control trial.

IL-12

IFN-γ

2017

Castiglioni S. et al.

International Journal of Molecular Sciences

In vitro basic research

Femtograms of Interferon-gamma Suffice to Modulate the Behavior of Jurkat Cells: A New Light in Immunomodulation.

IFN-γ
2018

Mancini F. et al.

International Immunopharmacology

In vitro basic research

Low Dose SKA progesterone and Interleukin-10 modulate inflammatory pathway cytokines in endometriotic cell lines.

IL-10

PROGESTERON

2018

Uberti F. et al.

Wound

In vivo basic research

Highly Diluited Acetylcholine Promotes Wound Repair in an In Vivo Model

ACH

2018

Tagliacarne S. C. et al.

Immunology Letters

Ex vivo basic research

Low Dose multicomponent medication modulates humoral and cellular immune response in an ex-vivo study on children subjected to adenoid surgery.

CITOMIX

2020

Molinari C. et al.

Brain Sciences

In vitro and in animal model basic research

The Role of BDNF on Aging-Modulation Markers.

BDNF

Submitted Papers

Year

Authors

Journal

Research type

Title

Tested Molecules

2015

Galli E. et al.

Submitted

Clinical Trial

Clinical and immunological evaluation of long-term treatment with Low Dose Medicine in pediatric population affected by chronic Atopic Dermatitis. Experimental randomized double-blind at two stages clinical trial.

IL-12

IFN-γ

2015

Fiorito F. et al

Submitted

Clinical Trial (veterinary)

Clinical improvement in feline herpesvirus-1 infected cats by oral low doses of interleukin-12 and interferon-gamma.

IL-12

IFN-γ

2016

Migliore A. et al.

Submitted

Clinical Trial

Treatment of Rheumatoid Arthritis with low dose SKA compared to standard treatment.

Anti IL-1

IL-10

IL-4

Research Works On Going

Year

Authors

Journal

Research type

Title

Food Supplement

2016

Matucci M. et al.

Giornale Italiano di Ostetricia e Ginecologia

Pilot Clinical Study

Effectiveness of low dose SKA Anti IL-1 and IL-10 in Early Stage Symptomatic Osteoarthritis.

Anti IL-1

IL-10

Research Works In Pipeline

Year

Authors

Journal

Research type

Title

Food Supplement

2016

Torta R. et al.

 

Clinical Trial

Fibromyalgia and low grade inflammation: effectiveness and safety of low dose Interleukin-10 in a double blind randomized placebo controlled clinical trial.

IL-10

2016

Masieri S. et al.

 

Clinical Trial

Effects of low dose SKA Interleukin-10 and TGF-Beta in nasal polyps.

IL-10

TGF-β

2016

De Cicco F. et al.

 

In vivo and in vitro basic research

Efficacy of low dose SKA interleukins and hormones in an animal model and cell cultures of Endometriosis.

Anti IL-1

IL-10

Progesterone